Evidence map›Paper›PMID 26091297›Full record

ArticleAIDS (London, England)2015

Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection.

Elizabeth A Miller, Ramya Gopal, Vanessa Valdes, Jeffrey S Berger, Nina Bhardwaj, Meagan P O'Brien

Registry-linked trialAbstract read
In one paragraph

Article in AIDS (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02578706 (Targeting Platelets in Chronic HIV Infection), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02578706 phase2completednot on this map

Targeting Platelets in Chronic HIV Infection

TypeinterventionalSponsorIcahn School of Medicine at Mount SinaiRan2015 to 2016Enrolled27ConditionsHIV-1 InfectionArmsClopidogrel, Aspirin, Placebo
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. CD40L and Its Receptors in Atherothrombosis-An Update.Frontiers in cardiovascular medicine · 2017
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Elizabeth A MilleraDivision of Infectious Diseases, Department of Medicine bDivision of Hematology and Oncology, Hess Center for Science and Medicine, Icahn School of Medicine at Mount Sinai cDivision of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA.
Ramya Gopal
Vanessa Valdes
Jeffrey S Berger
Nina Bhardwaj
Meagan P O'Brien
Apple (Israel) · IL

Funding

Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
VIROLOGY COREP30AI027742 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GORNY, MIROSLAW K · 1989 to 2010
$19.4M
Institutional Clinical and Translational Science AwardUL1TR000038 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL, HOCHMAN, JUDITH S · 2012 to 2014
$16.8M
Modulating anti-HIV immunity by plasmacytoid dendritic cellsR01AI081848 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BHARDWAJ, NINA · 2010 to 2021
$4.5M
Induction of Immunity by Non-Replicating HIV-1R37AI044628 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BHARDWAJ, NINA · 2004 to 2014
$4.2M
IN VIVO INDUCTION OF HIV SPECIFIC CTL BY DENDRITIC CELLSR01AI044628 · NIAID · ROCKEFELLER UNIVERSITY · PI BHARDWAJ, NINA · 1999 to 2003
$2.3M
HIV Dysregulation of Human Plasmacytoid Dendritic CellsK08AI093153 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI O'BRIEN, MEAGAN P · 2011 to 2015
$659k
Use of a Novel Antigen Loading Platform for Dendritic Cell-Based HIV VaccinesK08AI084578 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MILLER, ELIZABETH ANNE · 2009 to 2013
$658k
NCATS NIH HHS UL1 TR000038NCATS NIH HHS UL1 TR001445NIAID NIH HHS K08 AI084578NIAID NIH HHS K08 AI093153NIAID NIH HHS K08 AI84578NIAID NIH HHS P30 AI027742NIAID NIH HHS P30AI027742NIAID NIH HHS R01 AI044628NIAID NIH HHS R01 AI081848NIAID NIH HHS R37 AI044628PHS HHS U01A1067854
6 · The paper itself

Abstract

objectivePlasma soluble CD40 ligand (sCD40L) is increased during HIV-1 infection, but it is unknown whether it circulates in monomeric or multimeric forms, and whether the circulating forms have differential effects on myeloid dendritic cell function and adaptive regulation.

designsCD40L forms were measured in plasma samples from HIV-infected donors. The effects of sCD40L forms on dendritic cell function were measured in vitro.

methodsTo delineate which forms of sCD40L are present in plasma from HIV-infected donors, immunoblots were performed following enrichment of plasma for medium and low-abundance proteins. Dendritic cells from seronegative donors were exposed to multiple forms of sCD40L prior to Toll-like receptor stimulation and dendritic cell function and adaptive regulation was assessed in vitro.

resultsMonomeric and multimeric forms of sCD40L were identified in plasma from antiretroviral therapy-treated HIV-infected donors. Although monomeric and multimeric forms of sCD40L had differential effects on dendritic cell activation when given alone, both strongly suppressed secretion of the Th1 skewing cytokine, interleukin-12, upon subsequent Toll-like receptor stimulation. Furthermore, dendritic cells exposed to both monomeric and multimeric sCD40L induced regulatory T-cell formation and T-cell anergy.

conclusionElevated sCD40L during HIV infection impairs dendritic cell function, contributing to innate and adaptive immune dysfunction. Antiretroviral adjunctive therapies that decrease sCD40L may provide immune modulatory benefits.

Indexed as

CD40 LigandCells, CulturedCross-Sectional StudiesDendritic CellsHIV-1HIV InfectionsHumansInterleukin-12T-Lymphocytes, RegulatoryToll-Like ReceptorsCD40 LigandInterleukin-12Toll-Like Receptors

Identifiers

PMID26091297
PMCPMC4478195
OpenAlexW2417934743

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.